AU2018269557B2 - Formulations of homotaurines and salts thereof - Google Patents

Formulations of homotaurines and salts thereof Download PDF

Info

Publication number
AU2018269557B2
AU2018269557B2 AU2018269557A AU2018269557A AU2018269557B2 AU 2018269557 B2 AU2018269557 B2 AU 2018269557B2 AU 2018269557 A AU2018269557 A AU 2018269557A AU 2018269557 A AU2018269557 A AU 2018269557A AU 2018269557 B2 AU2018269557 B2 AU 2018269557B2
Authority
AU
Australia
Prior art keywords
formulation
hpmc
release
pellets
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269557A
Other languages
English (en)
Other versions
AU2018269557A1 (en
Inventor
Badrinath DONIPARTHI
Steven Johns
Kenneth PAYIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Confluence Pharmaceuticals LLC
Original Assignee
Confluence Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals LLC filed Critical Confluence Pharmaceuticals LLC
Publication of AU2018269557A1 publication Critical patent/AU2018269557A1/en
Application granted granted Critical
Publication of AU2018269557B2 publication Critical patent/AU2018269557B2/en
Priority to AU2021225172A priority Critical patent/AU2021225172B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018269557A 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof Active AU2018269557B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021225172A AU2021225172B2 (en) 2017-05-17 2021-08-31 Formulations Of Homotaurines And Salts Thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US62/507,532 2017-05-17
US201862660690P 2018-04-20 2018-04-20
US62/660,690 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021225172A Division AU2021225172B2 (en) 2017-05-17 2021-08-31 Formulations Of Homotaurines And Salts Thereof

Publications (2)

Publication Number Publication Date
AU2018269557A1 AU2018269557A1 (en) 2019-11-28
AU2018269557B2 true AU2018269557B2 (en) 2021-06-03

Family

ID=64274653

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018269557A Active AU2018269557B2 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof
AU2021225172A Active AU2021225172B2 (en) 2017-05-17 2021-08-31 Formulations Of Homotaurines And Salts Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021225172A Active AU2021225172B2 (en) 2017-05-17 2021-08-31 Formulations Of Homotaurines And Salts Thereof

Country Status (8)

Country Link
US (1) US12042566B2 (enExample)
EP (1) EP3624788A4 (enExample)
JP (2) JP2020519669A (enExample)
KR (1) KR20200005576A (enExample)
AU (2) AU2018269557B2 (enExample)
IL (1) IL270654B2 (enExample)
WO (1) WO2018213589A1 (enExample)
ZA (1) ZA201908264B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) * 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DK1073432T3 (da) 1998-04-14 2007-12-17 Gen Hospital Corp Anvendelse af D serin eller D alanin til behandling af skizofreni
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2375048C2 (ru) 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2504471A1 (en) 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
EP2167068A2 (en) 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
SI2395990T1 (sl) 2009-02-12 2015-04-30 Indiana University Research And Technology Corporation Offic Of Technology Transfer Snov in postopki za zdravljenje razvojne motnje, vključno s komorbidnim in idiopatskim avtizmom
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2796132B1 (en) * 2011-03-01 2018-05-02 Pharnext Baclofen and acamprosate based therapy of neurological disorders
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014018468A1 (en) 2012-07-22 2014-01-30 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015217796B2 (en) * 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
EP3331518A4 (en) 2015-08-04 2019-04-03 Confluence Pharmaceuticals, LLC COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) * 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Also Published As

Publication number Publication date
EP3624788A1 (en) 2020-03-25
JP2020519669A (ja) 2020-07-02
US12042566B2 (en) 2024-07-23
IL270654B1 (en) 2024-03-01
CA3062834A1 (en) 2018-11-22
AU2021225172B2 (en) 2023-04-06
US20200163895A1 (en) 2020-05-28
KR20200005576A (ko) 2020-01-15
WO2018213589A1 (en) 2018-11-22
ZA201908264B (en) 2022-03-30
IL270654A (en) 2020-01-30
EP3624788A4 (en) 2021-03-03
AU2021225172A1 (en) 2021-09-30
JP7499539B2 (ja) 2024-06-14
AU2018269557A1 (en) 2019-11-28
JP2023099100A (ja) 2023-07-11
IL270654B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CA2830788C (en) Methods and compositions for treatment of attention deficit disorder
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
AU2005307052B2 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
KR102790656B1 (ko) 아캄프로세이트의 스프링클 제형
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
US8927010B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
CA3062834C (en) Formulations of homotaurines and salts thereof
RU2833481C2 (ru) Распадающаяся в ротовой полости фармацевтическая композиция, содержащая нефопам, и способ ее получения
AU2010351281B2 (en) Ciprofloxacin dry syrup composition
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
RU2744270C2 (ru) Прессованный фармацевтический препарат
US20150238615A1 (en) Denaturants for sympathomimetic amines
TR201613300A1 (tr) Anti̇muskari̇ni̇k farmasöti̇k terki̇pler
TR201603387A1 (tr) Gastroi̇ntesti̇nal hastaliklarin tedavi̇si̇nde kullanilan farmasöti̇k formülasyonlar

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)